Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christophe Rochais

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Anti-Cancer Agents in Medicinal Chemistry|May 21, 2015
Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer ActivitiesMaria de Fatima Pereira, Christophe Rochais, Patrick Dallemagne
Future Medicinal Chemistry|May 16, 2017
Modulating 5-HT<sub>4</sub> and 5-HT<sub>6</sub> receptors in Alzheimer's disease treatmentJulien Lalut, Delphine Karila, Patrick Dallemagne, et al.
Pharmaceutics|October 28, 2023
Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer's DiseaseThomas Guiselin, Cédric Lecoutey, Christophe Rochais, et al.
The Journal of Pharmacy and Pharmacology|April 18, 2020
Drug repositioning: a brief overviewJean-Pierre Jourdan, Ronan Bureau, Christophe Rochais, et al.
Journal of Medicinal Chemistry|May 28, 2020
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and ChallengesPauline Zipfel, Christophe Rochais, Kévin Baranger, et al.
Expert Opinion on Therapeutic Patents|May 14, 2020
Therapeutic modulators of the serotonin 5-HT<sub>4</sub> receptor: a patent review (2014-present)Caroline Lanthier, Patrick Dallemagne, Cédric Lecoutey, et al.
Bioorganic & Medicinal Chemistry|October 14, 2009
Synthesis, reactivity and biological evaluation of novel halogenated tripentonesVittoria Perri, Christophe Rochais, Thierry Cresteil, et al.
Expert Opinion on Drug Discovery|January 28, 2022
Advances in prodrug design for Alzheimer's disease: the state of the artValentin Travers-Lesage, Serge M Mignani, Patrick Dallemagne, et al.
Molecular Informatics|April 15, 2024
Discovery of a pocket network on the domain 5 of the TrkB receptor - A potential new target in the quest for the new ligandsMirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, et al.
European Journal of Medicinal Chemistry|April 14, 2020
hERG toxicity assessment: Useful guidelines for drug designAmanda Garrido, Alban Lepailleur, Serge M Mignani, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Anti-Cancer Agents in Medicinal Chemistry|May 21, 2015
Recent Advances in Phenanthroindolizidine and Phenanthroquinolizidine Derivatives with Anticancer ActivitiesMaria de Fatima Pereira, Christophe Rochais, Patrick Dallemagne
Future Medicinal Chemistry|May 16, 2017
Modulating 5-HT<sub>4</sub> and 5-HT<sub>6</sub> receptors in Alzheimer's disease treatmentJulien Lalut, Delphine Karila, Patrick Dallemagne, et al.
Pharmaceutics|October 28, 2023
Conceptual Framework of the Design of Pleiotropic Drugs against Alzheimer's DiseaseThomas Guiselin, Cédric Lecoutey, Christophe Rochais, et al.
The Journal of Pharmacy and Pharmacology|April 18, 2020
Drug repositioning: a brief overviewJean-Pierre Jourdan, Ronan Bureau, Christophe Rochais, et al.
Journal of Medicinal Chemistry|May 28, 2020
Matrix Metalloproteinases as New Targets in Alzheimer's Disease: Opportunities and ChallengesPauline Zipfel, Christophe Rochais, Kévin Baranger, et al.
Expert Opinion on Therapeutic Patents|May 14, 2020
Therapeutic modulators of the serotonin 5-HT<sub>4</sub> receptor: a patent review (2014-present)Caroline Lanthier, Patrick Dallemagne, Cédric Lecoutey, et al.
Bioorganic & Medicinal Chemistry|October 14, 2009
Synthesis, reactivity and biological evaluation of novel halogenated tripentonesVittoria Perri, Christophe Rochais, Thierry Cresteil, et al.
Expert Opinion on Drug Discovery|January 28, 2022
Advances in prodrug design for Alzheimer's disease: the state of the artValentin Travers-Lesage, Serge M Mignani, Patrick Dallemagne, et al.
Molecular Informatics|April 15, 2024
Discovery of a pocket network on the domain 5 of the TrkB receptor - A potential new target in the quest for the new ligandsMirjana Antonijevic, Jana Sopkova-de Oliveira Santos, Patrick Dallemagne, et al.
European Journal of Medicinal Chemistry|April 14, 2020
hERG toxicity assessment: Useful guidelines for drug designAmanda Garrido, Alban Lepailleur, Serge M Mignani, et al.
Pageof 7